Loading
A phase 3 trial of Standard Chemotherapy in ovarian cancer, run by Cordgenics, LLC, active and no longer recruiting.
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer is a phase 3 interventional study registered as NCT03949283 by Cordgenics, LLC, with 150 participants enrolled, started 2019-07-26 and due to reach its primary completion in 2024-06-30. Interventions recorded: Standard Chemotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/